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Essentials
• Prothrombin and partial thromboplastin time (PT/PTT)
measure direct oral anticoagulants (DOACs).
• PT, PTT and specific tests for DOACs were performed
on patients treated for atrial fibrillation.
• Normal PT/PTT don’t exclude DOAC activity and their
prolongation doesn’t confirm DOAC action.
• The use of PT or PTT to evaluate DOAC activity could
cause dangerous misinterpretations.
Summary. Background: Prothrombin time (PT) and acti-
vated partial thromboplastin time (APTT) have been pro-
posed to measure the effect of oral anti-activated factor X
(FXa) or anti-activated FII drugs, respectively. Aims: To
evaluate the relationships and responsiveness of PT and
APTT versus direct oral anticoagulant (DOAC) concentra-
tions measured with specific coagulation tests performed
with different platforms in four Italian anticoagulation
clinics. Methods: Six hundred and thirty-five patients with
atrial fibrillation participated in the study: 240 were receiv-
ing dabigatran, 264 were receiving rivaroxaban, and 131
were receiving apixaban. Blood was taken at trough and
peak within the first month (15–25 days) of treatment. PT,
APTT, diluted thrombin time (dTT) calibrated for dabiga-
tran and anti-FXa calibrated for rivaroxaban or apixaban
were determined. Results: For dabigatran, the correlation
between APTT and dTT ranged from r = 0.80 to r = 0.62.
For rivaroxaban, the correlation between the anti-FXa
assay and PT ranged from r = 0.91 to r = 0.73. For apixa-
ban, the correlation between the anti-FXa assay and PT
was lower than for the two other drugs (r = 0.81 to
r = 0.54). Despite the above significant correlations, the
responsiveness of PT or APTT was relatively poor. A dis-
crepancy between global testing and DOAC plasma con-
centrations was shown in a considerable proportion of
patients, depending on the platform and drug, with values
ranging from 6% to 62%. Conclusions: Overall, poor
responsiveness of the screening tests to DOAC concentra-
tions was observed. PT and APTT normal values cannot
exclude DOAC anticoagulant activity, and PT or APTT
prolongation is not always associated with DOAC antico-
agulant effect as determined with specific tests.
Keywords: activated partial thromboplastin time;
anticoagulant drugs; atrial fibrillation; blood coagulation
test; prothrombin time.
Introduction
Oral anticoagulant therapy is recommended for the treat-
ment and prevention of venous and arterial thromboem-
bolism [1]. Until a few years ago, vitamin K antagonists
(VKAs) were the only available drugs; however, owing to
their pharmacologic characteristics, these require frequent
laboratory monitoring and expert dose adjustment. More
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recently, the direct oral anticoagulants (DOACs) have
been introduced into clinical practice for the prevention
of stroke and systemic embolism in patients with atrial
fibrillation, and for the prevention and treatment of
venous thromboembolism. In contrast to VKAs, the use
of DOACs has been proposed without the need for labo-
ratory testing and dose adjustment, because phase III
clinical trials showed efficacy and safety at fixed doses
based only on clinical criteria [2–5].
However, there are situations in which DOAC antico-
agulant activity should be measured. These include bleed-
ing or thromboembolic events, before surgery/invasive
procedures, and when a decision on thrombolytic therapy
in stroke patients needs to be made. Furthermore, testing
could be useful in a number of other situations, including:
(i) patients with renal/liver disease; (ii) whenever a possi-
ble interaction with other drugs is suspected; (iii) in
patients with extreme body weight; (iv) to assess adher-
ence to the therapy; and (v) when overcoagulation/under-
anticoagulation is suspected [6–9]. In addition, because
specific antidotes will soon become available, DOAC
measurement might be useful to ensure their appropriate
administration in cases of immediate reversal of anticoag-
ulation, to prevent overuse of these expensive medications
[10,11].
Originally, prothrombin time (PT) and activated partial
thromboplastin time (APTT) were proposed as methods
for measuring the levels of oral anti-activated factor X
(FXa) drugs and dabigatran, respectively, because of their
simplicity and prompt availability [12–14]. The implicit
assumption was that PT and APTT are responsive and
specific for DOACs. However, it was not considered that
they may be potentially affected by interference. PT and
APTT are, in fact, functional global tests that measure
the time of clot formation, which can be altered in several
clinical conditions, including liver disease, acquired/con-
genital factor deficiencies, or the presence of antiphospho-
lipid antibodies [15]. Furthermore, because of their anti-
FXa or anti-activated FII activity, DOACs may interact
differently with screening coagulation tests, depending on
the composition of the reagents and the type of coagu-
lometer used for testing [16–22]. Finally, there might be
considerably different levels of responsiveness of PT and
APTT to increasing DOAC concentrations. All of these
analytic and biological variables can significantly affect
PT and APTT, thus limiting their value for measuring
DOAC in practice. Although the limitations of PT and
APTT have been highlighted by previous studies [18–22],
the numbers of investigated patients were relatively small,
or investigations were based on limited numbers of testing
platforms. In this study, we sought to evaluate the
relationship between DOAC concentrations, measured
with specific tests, and PT and APTT, measured with
different commercial platforms, for a relatively large
number of patients treated with the three DOACs
presently available.
Design, patients, and methods
Design
This was an observational multicenter multiplatform study
on patients treated with dabigatran, rivaroxaban, or apixa-
ban, and was approved by the ethical committee of the gen-
eral hospital of Cremona. Four large Italian
anticoagulation clinics (Bologna [A], Cremona [B], Padua
[C], and Florence [D]), affiliated with the Italian Federation
of Anticoagulation Clinics and engaged in the Survey on
Anticoagulated Patients (START) Register (www.start-
register.org), were asked to join the collaborative study by
collecting and testing plasma from patients treated with
DOACs.
Patients
Dabigatran, rivaroxaban and apixaban were introduced at
different time from June 2013, and medical prescription
was allowed with different rules in individual Italian
regions. Consequently, during the study period (year 2014),
the four anticoagulation clinics enrolled patients receiving
dabigatran and rivaroxaban, whereas only three of them
enrolled patients receiving apixaban (A, B, and D). After
giving informed consent, 635 consecutive patients with
atrial fibrillation seen at the anticoagulation clinics from 1
January 2014 to 31 December 2014 were enrolled in the
study, provided that they had been treated with DOACs
for at least 1 week and were available to attend the clinics
for blood sampling at the specified time points (see below).
Two hundred and forty patients were receiving dabigatran
(122 and 118 taking 150 mg or 110 mg twice daily, respec-
tively), 264 were receiving rivaroxaban (183 and 81 taking
20 mg or 15 mg once daily, respectively), and 131 were
receiving apixaban (98 and 33 taking 5 mg or 2.5 mg twice
daily, respectively). Patients were evaluated at enrollment,
and the type and the dose of drug were prescribed at the
discretion of the attending physician, on the basis of both
clinical characteristics and renal function. Patients were
followed within the first month of treatment (from 15 days
to 25 days from the beginning), when trough and peak
blood samples were taken. The trough sample was
obtained 12 h after the last dose intake for dabigatran and
apixaban, and 24 h after the last dose intake for rivaroxa-
ban. The peak sample was obtained 2 h after ingestion of
the drug, ensuring concomitant food intake for patients
receiving rivaroxaban. Plasma samples were collected in
vacuum plastic tubes (Vacutainer; Becton Dickinson, Ply-
mouth, UK), containing 3.2% trisodium citrate (9 : 1 v/v,
blood/anticoagulant). Blood was centrifuged at 2000 9 g
for 20 min, and plasma was quickly frozen and stored at
 80 °C until testing. One thousand two hundred and sev-
enty blood samples were collected in the four clinics and
used for analysis: 480 for dabigatran, 528 for rivaroxaban,
and 262 for apixaban (Table S1).
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Laboratory tests
PT and APTT, expressed as a ratio (patient clotting
times/normal clotting times), were measured with the
combination reagent/instrument as detailed in Table 1.
DOAC anticoagulant activity, expressed as drug concen-
tration-equivalent (ng mL1), was also measured accord-
ing to diluted thrombin time (dTT) calibrated for
dabigatran [23], and specific anti-FXa assays calibrated
for rivaroxaban or apixaban [24–27]. Testing was per-
formed in each clinic with appropriate coagulation plat-
forms, according to the manufacturers’ recommendations.
Statistical analysis
Linear regression (least-squares method) was used to eval-
uate the relationship between DOAC concentrations as
measured with specific tests and the prolongation of PT
or APTT for each clinic. Responsiveness, defined as the
extent of prolongation of PT or APTT at increasing
DOAC concentrations, was assessed for each clinic and
drug as follows. The entire range of concentrations
observed in the investigated patients (i.e. from
< 30 ng mL1 to > 350 ng mL1) was subdivided into
classes of 20 ng mL1 each. These concentrations were
then plotted (vertical axis) against the corresponding PT
or APTT ratio, and the results were compared with the
upper limit of the reference interval. The responsiveness
was also evaluated by interpolation of the drug (arbi-
trary) concentration of 200 ng mL1 from the regression
lines to determine the corresponding PT or APTT ratio.
By definition, the higher the PT or APTT ratio, the
greater the test responsiveness.
Statistical analyses were performed with GRAPHPAD
software (GraphPad, San Diego, CA, USA); a two-sided
P-value of ≤ 0.05 was considered to be statistically
significant.
Results
Six hundred and thirty-five patients were enrolled, and
1270 blood samples were tested. The distributions of
numbers of patients and numbers of samples in each
clinic are shown in Table 1. Peak values were significantly
higher than trough values for each drug and clinic,
regardless of the test used (Table S2).
Relationship of DOAC plasma concentration with PT or
APTT
We analyzed the relationship of the concentrations of
dabigatran and anti-FXa drugs with APTT and PT,
respectively. For this analysis, peak and trough values
were combined in order to increase the numbers of obser-
vations. Regression lines, equations describing the rela-
tionship of drug concentration with PT or APTT ratio,
correlation coefficients (r-values) and coefficients of deter-
mination (r2-values) are summarized in Figs S1–S3. For
dabigatran, the correlation between APTT and dTT ran-
ged from r = 0.80 to r = 0.62. For rivaroxaban, the corre-
lation between the anti-FXa assay and PT ranged from
r = 0.91 to r = 0.73. For apixaban, the correlation
between the anti-FXa assay and PT was lower than for
the other two drugs (r = 0.81 to r = 0.54). Although r-
values were acceptable in most cases, the slopes of the
regression lines were relatively small, indicating that the
PT and APTT tests were not particularly responsive to
the DOAC plasma concentrations (see below).
Responsiveness of PT and APTT to increasing DOAC
concentrations
The responsiveness of PT or APTT to DOAC concentra-
tion was assessed by selecting classes of DOAC concen-
trations from low to high, and comparing them with PT
Table 1 Patients and number of samples, instruments, reagents, prothrombin time (PT) and activated partial thromboplastin time (APTT)
upper limits of normal range used in the four anticoagulation clinics
Clinic A Clinic B Clinic C Clinic D
Dabigatran (patient no./sample no.) 47/94 70/158 89/178 25/50
Rivaroxaban (patient no./sample no.) 72/144 108/216 61/122 23/46
Apixaban (patient no./sample no.) 30/60 91/182 – 10/20
Coagulometer STA compact (Stago) STA-R (Stago) CA 7000 (Sysmex) ACL TOP 700 (Werfen)
Reagents
PT Recombiplastin (Werfen) Neoplastin (Stago) Innovin (Siemens) Recombiplastin (Werfen)
APTT Actin (Siemens) PTT (Stago) Actin-FS (Siemens) SynthASil (Werfen)
Dabigatran Thrombin Siemens Thrombin Stago Hyphen Hemoclot Hyphen Hemoclot
Rivaroxaban Liquid Anti-Xa Stago Liquid Anti-Xa Stago Hyphen DiXal Hyphen DiXal
Apixaban Liquid Anti-Xa Stago Liquid Anti-Xa Stago – Technochrome anti-Xa Kit
Calibrators
Dabigatran Hyphen Biomed Hyphen Biomed Hyphen Biomed Hyphen Biomed
Rivaroxaban Calibrator Stago Calibrator Stago Biophen Rivaroxaban Hyphen Biomed
Apixaban Calibrator Stago Calibrator Stago – Technoview Apixaban
PT upper limit of normal range < 1.20 < 1.20 < 1.13 < 1.20
APTT upper limit of normal range < 1.25 < 1.22 < 1.30 < 1.27
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or APTT. The results are shown in Figs 1–3. APTT was
still within normal limits when dabigatran concentrations
were 51–70 ng mL1 (clinics A, B, and C) and 131–
150 ng mL1 (clinic D) (Fig. 1). PT was still within
normal limits when rivaroxaban concentrations were
91–110 ng mL1 (clinic A), 51–70 ng mL1 (clinic B),
and 171–190 ng mL1 (clinic D) (Fig 2). PT was still
within normal limits when apixaban concentrations were
151–170 ng mL1 (clinic A) and 231–250 ng mL1 (clinic
B) (Fig 3). Detailed analysis of the agreement of PT or
APTT with DOAC concentrations are shown in Table 2.
There were many instances of PT or APTT results still
being normal when the DOAC concentrations were
> 50 ng mL1 and vice versa.
The responsiveness of the screening tests to increasing
DOAC concentrations was also evaluated by interpolation
of the drug (arbitrary) concentration of 200 ng mL1 from
the regression lines to determine the corresponding PT or
APTT ratio. As shown in Table 2 and Figs S1–S3, the
APTT ratio corresponding to 200 ng mL1 dabigatran
varied from 1.7 (clinic A) to 2.0 (clinic C). The PT ratio
corresponding to 200 ng mL1 rivaroxaban varied from
1.3 (clinic C) to 1.9 (clinic B). The PT ratio corresponding
to 200 ng mL1 apixaban was 1.3 (clinics A, B, and D).
Discussion
Previous studies showed poor responsiveness of the coagu-
lation screening tests for DOAC measurements in relation
to type of reagent used. Even though some reagents
showed acceptable responsiveness to a specific drug (e.g.
neoplastin and recombiplastin for rivaroxaban [28], this
conclusion cannot be extended to all drugs and all plat-
forms available on the market. In fact, different reagents
not only show different levels of responsiveness to DOAC,
but also show different levels of responsiveness to individ-
ual coagulation factors. This variability creates difficulties
in their application for patients receiving treatment, and
the harmonization of results across laboratories.
Even though specific tests are not yet widely used in
routine clinical practice, dTT and the ecarin tests (clotting
or chromogenic) for dabigatran and the chromogenic
anti-FXa assays for the anti-FXa drugs are commercially
available. They show good linearity and responsiveness to
DOACs, and the results can be expressed as drug concen-
tration-equivalents [23–27] by the use of specific calibra-
tors that are commercially available. The results obtained
with the above tests correlated with the results obtained
with mass spectrometry [29,30].
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Fig. 1. Activated partial thromboplastin time (APTT) ratio median values and ranges obtained for different arbitrary classes of dabigatran
concentrations. (A)–(D) represent results obtained at different clinics. Dotted lines represent the upper limit of the normal range.
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There is an ongoing debate in the literature regarding
DOAC laboratory testing. Some authors argue that speci-
fic tests should be recommended for DOAC measure-
ments, highlighting the inappropriateness of PT or APTT
[31,32], whereas others suggest that PT or APTT should
be used, if not to quantify DOACs, at least to assess for
the presence/absence of drug and the anticoagulant activ-
ity [12–14].
The present study, carried out on a large number of
patients, confirms the poor concordance between DOAC
plasma concentrations and PT or APTT, highlighting that
a normal test result is not always associated with the
absence of or minimal residual concentrations of drugs.
These observations raise concerns about the value of PT
or APTT for assessing the individual anticoagulant activ-
ity of DOACs or for assessing the presence or absence of
circulating drugs. This aspect represents a clinical prob-
lem, because of the risk of misinterpretation, which may
endanger patients. As an example, patients who present
with normal PT or APTT could be erroneously consid-
ered to be safe for surgery; on, in contrast, surgery,
invasive procedures or thrombolysis could be postponed
or contraindicated in patients showing prolonged
PT or APTT. In addition, the availability of specific
antidotes to be used for immediate neutralization of
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Fig. 2. Prothrombin time (PT) ratio median values and ranges
obtained for different arbitrary classes of rivaroxaban concentra-
tions. (A), (B) and (D) represent results obtained at different clinics.
Dotted lines represent the upper limit of the normal range.
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Fig. 3. Prothrombin time (PT) ratio median values and ranges
obtained for different arbitrary classes of apixaban concentrations.
(A) and (B) represent results obtained at different clinics. Dotted
lines represent the upper limit of the normal range.
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anticoagulation in patients with life-threatening hemor-
rhage might call for DOAC measurement to ensure
appropriate use of these medications [11]. They would
therefore require specific and reliable DOAC testing,
which cannot be guaranteed with PT or APTT.
On the other hand, PT and APTT show many of the
characteristics that make them ‘ideal’ (e.g. inexpensive,
widely available, and rapid), but, as shown in this and
other reports, they are not adequately responsive to the
DOAC concentrations. These limitations could be over-
come by the use of specific tests. They are now commer-
cially available from many manufacturers, can be easily
set up in any of the ordinary coagulometers, and can be
performed even in emergency situations without special
expertise. Even though they are more expensive than PT
or APTT, their use in special and selected situations will
ultimately counterbalance their costs.
The strengths of our evaluation are the real-life nature
of the study, dealing with a large number of samples from
anticoagulated patients, and the use of different commer-
cial platforms in four different clinics. Some limitations
of the study should be recognized. First, we did not mea-
sure DOAC concentrations with gold standard methods
that would have made comparison with PT and APTT
more valuable. However, previous studies have shown
that specific tests for DOAC are highly correlated with
mass spectrometry results for the measurement of DOAC
concentrations [29,30]. Second, we could not directly
compare the different platforms for PT and APTT, as
samples collected in different clinics were not centralized
for measurement within the same laboratory. However, it
should be recognized that, although a direct comparison
is not possible, the indirect comparison is still valuable
for giving some indication of which brand are more or
less responsive to DOACs. Third, owing to the limited
experience with DOACs, clinical endpoints relating
adverse events (hemorrhage or thrombosis) with DOAC
plasma concentrations are not available, so a fair compar-
ison between PT/APTT and specific tests is not possible.
A clinically meaningful comparison would require retrie-
val of data from clinical trials, as was done for
dabigatran by Reilly et al. [32], but this was beyond the
scope of the present study. Fourth, we did not assess the
reasons why PT/APTT and the specific tests do not agree.
For this evaluation, a larger sample of well-characterized
patients would have been required.
In conclusion, the present study shows that: (i) PT and
APTT react differently to DOACs in relation to the type of
drug and to the type of reagent, suggesting that each labo-
ratory should be aware of the performance of the reagent
used; (ii) patients having the same DOAC plasma concen-
trations may present with different PT or APTT results;
and (iii) normal APTT or PT test results obtained in
patients treated with dabigatran or anti-FXa drugs, respec-
tively, cannot exclude significantly high plasma concentra-
tions of the relevant DOAC, especially with poorly
responsive APTT or PT reagents. Consequently, the use of
PT or APTT in clinical practice to evaluate DOAC antico-
agulant activity could cause dangerous misinterpretations.
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Table 2 Responsiveness of prothrombin time (PT) or activated partial thromboplastin time (APTT) to direct oral anticoagulants (DOACs)
Clinic A Clinic B Clinic C Clinic D
Dabigatran (APTT), ratio (95% CI) 1.67 (1.61–1.75) 1.74 (1.66–1.80) 1.97 (1.82–2.14) 1.68 (1.63–1.75)
Rivaroxaban (PT), ratio (95% CI) 1.57 (1.54–1.62) 1.88 (1.85–1.94) 1.31 (1.26–1.38) 1.53 (1.49–1.59)
Apixaban (PT), ratio (95% CI) 1.28 (1.25–1.34) 1.29 (1.26–1.36) NA 1.32 (1.21–1.47)
Normal APTT and dabigatran > 50 ng mL1, n (%) 6/87 (6.9) 6/107 (5.6) 3/42 (7.1) 19/158 (12.0)
Prolonged APTT and dabigatran ≤ 50 ng mL1, n (%) 1/7 (14.3) 22/51 (43.1) 5/8 (62.5) 9/20 (45.0)
Normal PT and rivaroxaban > 50 ng mL1, n (%) 7/75 (9.3) 3/119 (2.5) 2/26 (7.7) 34/109 (31.2)
Prolonged PT and rivaroxaban ≤ 50 ng mL1, n (%) 7/69 (10.1) 11/97 (11.3) 5/20 (25.0) 3/13 (23.1)
Normal PT and apixaban > 50 ng mL1, n (%) 25/58 (43.1) 73/172 (42.4) NA 6/18 (33.3)
Normal PT and apixaban ≤ 50 ng mL1, n (%) 0/2 (0) 0/10 (0) NA 1/2 (50.0)
CI, confidence interval; NA, not available because clinic C did not enroll patients receving apixaban. Ratio (95% CI): the APTT or PT ratio
(95% CI) of patient clotting time/normal clotting time corresponding to a DOAC concentration of 200 ng mL1 (see also Figs 1–3). n (%):
number and percentage of discrepancies between global test results and DOAC anticoagulant activity measured with specific tests.
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online version of this article:
Fig. S1. Dabigatran and APTT ratio.
Fig. S2. Rivaroxaban and PT ratio.
Fig. S3. Apixaban and PT ratio.
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patients, and number of samples.
Table S2. DOAC measurement with specific and global
tests at peak and trough levels.
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